MAKROFAGLARNING (CD68+) IMMUN MIKROMUHITDAGI O'RNI VA ULARNING YUMSHAK TO'QIMA SARKOMALARINI DAVOLASH NATIJALARIGA TA'SIRI
##article.subject##:
sarkoma, makrofag, mikromuhit, kimyoterapiya, nur terapiyasi##article.abstract##
Ushbu maqola yumshoq to‘qimalar sarkomasining immun mikromuhitida makrofaglarning (CD68 markeri bilan belgilangan) rolini va ularning o‘tkazilayotgan terapiya samaradorligiga ta’sirini o‘rganishga bag‘ishlangan. Tahlil makrofaglarning o‘sma ichida va uning atrofida joylashishini, shuningdek, ularning davolashga javoblarning morfologik va klinik parametrlari bilan bog‘liqligini baholashni o‘z ichiga oladi. Natijalar shuni ko‘rsatdiki, o‘sma to‘qimasi ichida makrofaglarning mavjudligi sezilarli darajada morfologik regressiya va terapevtik patomorfozning yuqori darajasi bilan bog‘liq bo‘lib, bu M1 fenotipli makrofaglarning faol o‘smaga qarshi rolini ko‘rsatadi. Shu bilan birga, CD68 holati to‘liq yoki qisman javob kabi qisqa muddatli klinik ta’sirlarning prediktori emasligi aniqlandi. Tadqiqot yumshoq to‘qimalar sarkomasini aniqroq baholash va davolashni individuallashtirish uchun makrofaglarning funksional faolligini va ularning fenotipik holatini baholash muhimligini ta’kidlaydi. Olingan ma’lumotlar davolashda o‘sma strukturalari regressiyasida ishtirok etuvchi immun mexanizmlar haqidagi tushunchalarni kengaytirishga yordam beradi va immunoterapiyaning yangi strategiyalarini ishlab chiqish uchun asos bo‘lib xizmat qilishi mumkin.
Библиографические ссылки
Huang H, Fan Y, Zhang S, Bai X, Wang X, Shan F. Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review. Front Immunol. 2025 May 21;16:1507870. doi: 10.3389/fimmu.2025.1507870. PMID: 40469285; PMCID: PMC12133756
van der Graaf WTA, Orbach D, Judson IR, Ferrari A. Soft tissue sarcomas in adolescents and young adults: A comparison with their paediatric and adult counterparts. Lancet Oncol. (2017) 18:e166–e75. doi: 10.1016/s1470-2045(17)30099-2
Lee AQ, Hao C, Pan M, Ganjoo KN, Bui N. Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy. J Clin Oncol. (2024) 42:11569. doi: 10.1200/JCO.2024.42.16_suppl.11569
Wood GE, Meyer C, Petitprez F, D’Angelo SP. Immunotherapy in sarcoma: current data and promising strategies. Am Soc Clin Oncol Educ Book. (2024) 44:e432234. doi: 10.1200/edbk_432234
Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserocchi G, et al. Clinical and translational implications of immunotherapy in sarcomas. Front Immunol. (2024) 15:1378398. doi: 10.3389/fimmu.2024.1378398
Polatova Djamila , Madaminov Ahmad, Raximov Nodir . Significance of expression PD-L1 and p53 proteins in human papillomavirus-associated oropharyngeal squamous cell carcinoma// Journal of Biomedicine and Practice. 2022, vol . 7, issue 4, pp . 144-151
Abdurakhmonov F. R., Rakhimov N. M., Abdurakhmonova F. F. Special choices for the treatment of complications of the soft tissue injuries of the facial region //The American Journal of Medical Sciences and Pharmaceutical Research. – 2023. – Т. 5. – №. 10. – С. 24-26.